Actuate Therapeutics (ACTU) vs Citius Pharmaceuticals (CTXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 55.4% versus a loss of 96.4%. Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $13.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | CTXR |
|---|---|---|
| Share price | $0.2253 | $0.5085 |
| Market cap | $13.60M | $13.96M |
| 1-day change | +5.38% | +2.27% |
| YTD return | -96.32% | -34.56% |
| 1-year return | -96.43% | -55.39% |
| 5-year return | — | -98.79% |
| EPS (TTM) | $-0.76 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.23M | $-39.74M |
| 52-week high | $7.90 | $1.54 |
| 52-week low | $0.174 | $0.37 |
| Distance from 52-week high | -97.15% | -66.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +5084.20% | +686.63% |
| Average volume | 807.24K | 275.44K |
| Shares outstanding | 60.38M | 27.45M |
| Employees | 12 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed ACTU by 41.0 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ACTU vs CTXR FAQ
Which is bigger, Actuate Therapeutics or Citius Pharmaceuticals?
Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $13.60M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or CTXR?
CTXR returned -55.39% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Citius Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.